Special Committee on Aging Frontruns Valeant Pharmaceuticals Q1 Earnings Release

Entangled within the epic data dump the Senate Committee on Aging gave the world there is some troubling guidance provided by Valeant’s CFO, Rob Rosiello. In response to the interrogatories posed by the committee regarding the pricing of a handful of  Valeant Pharmaceuticals  drugs, Mr. Rosiello (response starts on pg 17) was required to disclose the ratio of revenues that each of those drugs represented in relation to company wide numbers. To set the baseline for those ratios, Mr. Rosiello provided the following table (pg. 21) of his response that details financial information for the company:

• i. Net Product Sales
• j. COGS
• k. Gross Margin
• l....
  

  Login required to continue reading.

  Setup a free account to get access to this article (no credit card required).

  View Full Article

  Already a member? Log in here